time (days) a % overall survival time (days) % overall survival supplemental figure 1 legend:...
DESCRIPTION
E545KNormal β-Actin Stat3 pY705 Erk1/2 pT202/204 42kDa 84kDa 42-4kDa H1047RRasE545K;RasH1047R;Ras SUPPLEMENTAL FIGURE 3 CACSTC SCC CAC Ras Stat3 C ;Ras A BTRANSCRIPT
Time (days)
A
% O
vera
ll S
urvi
val
Time (days)Time (days)
% O
vera
ll S
urvi
val
% O
vera
ll S
urvi
val
SUPPLEMENTAL FIGURE 1
Legend:MMTV-Cre, n = 71R26(Pik3ca), n = 285R26(Stat3), n = 46K-Ras(G12D), n = 10R26(Pik3caH1047R);MMTV-Cre, n = 112R26(Stat3C);MMTV-Cre, n = 30R26(Pik3caH1047R/Stat3C);MMTV-Cre, n = 48K-Ras(G12D);MMTV-Cre, n = 35R26(Pik3caH1047R);K-Ras(G12D);MMTV-Cre, n = 58R26(Stat3C);K-Ras(G12D);MMTV-Cre, n = 25| = censored data
B
0%
20%
40%
60%
80%
100%
Alive
Survived to 18 Months
Other
Lymphoma and/or Thymoma, no Mammary Tumors
Lymphoma and/or Thymoma, with Mammary Tumors
Mammary Gland Tumors
A B C
KA
SC
AME
SC
PDA
AME
SUPPLEMENTAL FIGURE 2
STC
SC
CAC
CAC
CAC
SC
E545KNormal
β-Actin
Stat3pY705
Erk1/2pT202/204
42kDa
84kDa
42-4kDa
H1047R Ras E545K;Ras H1047R;Ras
Normal
E545K
H1047R Ra
s
E545K;Ras
H1047R;Ras
0
10
20
30
40
50
Rela
tive
pErk
1/2
Expr
essi
on(n
orm
aliz
ed to
B-a
ctin)
Normal
E545K
H1047R Ra
s
E545K;Ras
H1047R;Ras
0
10
20
30
40
50
Rela
tive
pSta
t3 E
xpre
ssio
n(n
orm
aliz
ed to
B-a
ctin)
SUPPLEMENTAL FIGURE 3
CAC STC
SCC CAC
Ras
Sta
t3C;R
as
A
B
A) R
elapse
B) Survival
Relapse free (%)Disease free survival (%)
SUPPLEMENTAL FIGURE 4
PI3K
+ Stat3 P
athways
PI3K
+ Ras P
athways
Stat3 + R
as Pathw
aysP
I3K + S
tat3 + Ras P
athways
PI3K
+ Stat3 P
athways
PI3K
+ Ras P
athways
Stat3 + R
as Pathw
aysP
I3K + S
tat3 + Ras P
athways
Time (years)
Time (years)
Time (years)
Time (years)
Time (years)
Time (years)
Time (years)
Time (years)
A) Relapse (PI3K Pathway)
C) Relapse (Stat3 Pathway)
D) Death (Stat3 Pathway)
Rel
apse
free
(%)
B) Death (PI3K Pathway)
Basal-like
SUPPLEMENTAL FIGURE 5
Time (years)